Deep Tech Startups

Arisdyne provides process technologies for industrial applications, working with process engineers and plant managers to improve outcomes in areas such as biodiesel production, wastewater and biogas treatment, and graphene manufacturing. Its solutions aim to reduce catalyst consumption, increase throughput, boost methane production, and produce thin graphene platelets.

1 investor

Aristo develops a context-aware AI memory layer that lets users control their own data, focusing on on-device model optimization and efficient AI systems. It emphasizes performance alongside user privacy and data authority.

1 investor

ArmaBio develops a reprogrammable bioelectronic biosensing platform that detects biomarkers from small samples of blood, saliva, urine, or plasma with lab-grade accuracy in minutes. It provides this sensing layer as infrastructure for point-of-care, home, remote monitoring, pharma, and consumer health diagnostics companies.

1 investor

ArMatrix builds snake-like robotic arms designed to enter confined and hard-to-reach spaces without requiring human entry. The externally actuated arms contain no internal motors or electronics, targeting shipbuilding, heavy industry, and industrial maintenance in extreme environments.

1 investor

ARMGO develops a novel class of therapeutics called Rycals that target ryanodine receptors (RyRs) to correct calcium channel dysfunction in serious diseases with high unmet need. Its lead candidate, Surlorian, is being developed for heart failure by addressing an underlying driver of disease progression.

1 investor

Armmo develops defense technology focused on rapid iteration and combat-proven efficiency, with an emphasis on ITAR-free sovereignty.

1 investor

Armory Technologies develops origami-inspired composite materials (Origami Composites) that are lighter, stronger, and structurally optimized, with properties driven by geometric structure rather than molecular makeup. Its flagship ArmorONE panels serve applications such as truck body and trailer panels, air mobility crash safety, and geothermal energy systems.

1 investor

ARMR Sciences is developing conjugate vaccines and biologic countermeasures, including its lead candidate ARMR-100, designed to bind fentanyl in the bloodstream and prevent overdose from synthetic drugs. It targets high-risk populations such as first responders, military personnel, and individuals in recovery, working on a platform approach to address emerging drug threats.</parameter> <parameter name="sector_codes">["biotech", "healthtech", "deeptech"]

1 investor

Aronora is a clinical-stage biotech developing antithrombotic therapies, including factor XI/XIa inhibitors and thrombolytic drug candidates, to treat and manage thrombotic and thromboembolic conditions such as acute ischemic stroke, heart attack, and pulmonary embolism. Its pipeline of cardio-hematology programs targets patients requiring time-sensitive thrombolytic intervention or management of thrombosis risk.

1 investor

Arqus develops a security and defense layer for critical infrastructure such as airports, power plants, harbors, and electric grids, as well as for mobile terrestrial platforms and space assets like satellite constellations. Its offerings emphasize modular, autonomous systems with on-board autonomy for defending high-value physical and orbital infrastructure.

1 investor

ArrowBiome develops a microbiome platform technology with clinical validation and MIT-originated intellectual property, serving the beauty and ingredients industries. The company has demonstrated commercial traction with 47 engagements across 19 markets and is advancing toward profitability through its product applications.

1 investor

Articulus Surgical develops minimally invasive surgical robotic systems designed for India's Tier 2 and Tier 3 hospitals, where infrastructure and space are constrained. The company builds patient and surgeon-centric robotic platforms optimized for resource-limited surgical environments.

1 investor

Artielle Immunotherapeutics develops DRhQ, a therapeutic platform that targets the CD74 receptor and inhibits macrophage migration inhibitory factor (MIF) to treat neuroinflammatory conditions such as progressive multiple sclerosis and advanced cancers. The company builds on research from OHSU and the VA Portland Healthcare System.

1 investor

Artinis and NIRx build research-grade neuroimaging hardware and software, including fNIRS, oximetry, EEG, and HD-EMG systems for brain and physiological research. Their products serve scientific researchers worldwide.

1 investor

Artis BioSolutions develops synthetic DNA and provides integrated manufacturing services for genetic medicine and advanced therapeutic modalities, including cell therapy, gene therapy, mRNA, gene editing, and vaccines. The company serves genetic medicine developers seeking to accelerate clinical development and GMP manufacturing within a single quality framework.

1 investor

Arycs Technologies develops AI infrastructure systems that prioritize architectural efficiency and energy optimization through silicon photonics and coherent DSP technologies. The company serves enterprise and data center operators requiring high-performance, power-efficient optical network solutions.

1 investor

AS.CAR.I develops Advanced Driver Assistance Systems (ADAS) aimed at improving driving performance, safety, and reliability, including in extreme driving conditions.

1 investor

Asahi Surgical Robotics develops and manufactures surgical support robotic systems for medical facilities. The company focuses on improving quality of life for patients, families, and healthcare professionals through medical device innovation.

1 investor

A research and development-focused biotechnology company developing innovative medicines, centered on small-molecule drug discovery, to address dryness as a medical condition and unmet medical needs. Based in Tsukuba, Japan, it aims to deliver new treatment options to patients.

1 investor

ASAPI builds post-training data systems designed to make AI agent judgment dependable across long, complex projects. The company develops infrastructure aimed at improving agent reliability, planning, and adaptation.

1 investor

ASC manufactures printed circuit boards, including single-sided, double-sided, multilayer, and rigid-flex boards with capabilities such as ultra-fine lines down to 25 micron, RF circuits, and metal-clad boards for thermal management. It serves the military, aerospace, industrial, commercial, medical, telecom, computer, radar, and transportation markets.

1 investor

ASEM Technology develops a non-invasive measurement platform based on the ASEM method (acousto-electromagnetic method), which uses ultrasound to detect electric and magnetic polarization inside materials and visualize qualitative degradation or alteration. The technology, originating from research at Tokyo University of Agriculture and Technology, targets medical and healthcare applications (including a next-generation diagnostic device that visualizes and quantifies collagen fiber orientation and accumulation) and advanced non-destructive testing in industry.

1 investor

Asha Therapeutics uses physics-based computational methods to design drug molecules, operating at the intersection of computational chemistry and drug discovery. The company's approach aims to reduce time and cost in early-stage pharmaceutical development.

1 investor

AsimicA is a B2B strain engineering company that develops Microbial Stem Cell Technology (MiST) to repopulate microbial biofactories with young, productive cells during fermentation, reducing downtime and increasing yields. Its technology serves larger biotech fermentation companies producing industrial quantities of drugs, biofuels, materials, and food ingredients.

1 investor